Dynavax Technologies Dirección
Dirección controles de criterios 4/4
El CEO de Dynavax Technologies es Ryan Spencer , nombrado en Dec 2019, tiene una permanencia de 4.92 años. compensación anual total es $5.81M, compuesta por 13.1% salario y 86.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.17% de las acciones de la empresa, por valor de $2.80M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 6.4 años, respectivamente.
Información clave
Ryan Spencer
Chief Executive Officer (CEO)
US$5.8m
Compensación total
| Porcentaje del salario del CEO | 13.1% |
| Permanencia del CEO | 4.9yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 6.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$20m |
| Jun 30 2024 | n/a | n/a | US$17m |
| Mar 31 2024 | n/a | n/a | US$9m |
| Dec 31 2023 | US$6m | US$760k | -US$6m |
| Sep 30 2023 | n/a | n/a | US$61m |
| Jun 30 2023 | n/a | n/a | US$111m |
| Mar 31 2023 | n/a | n/a | US$236m |
| Dec 31 2022 | US$6m | US$695k | US$293m |
| Sep 30 2022 | n/a | n/a | US$320m |
| Jun 30 2022 | n/a | n/a | US$228m |
| Mar 31 2022 | n/a | n/a | US$104m |
| Dec 31 2021 | US$5m | US$600k | US$72m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$2m | US$515k | -US$75m |
| Sep 30 2020 | n/a | n/a | -US$97m |
| Jun 30 2020 | n/a | n/a | -US$138m |
| Mar 31 2020 | n/a | n/a | -US$129m |
| Dec 31 2019 | US$3m | US$391k | -US$156m |
Compensación vs. Mercado: La compensación total ($USD5.81M) de Ryan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.37M).
Compensación vs. Ingresos: La compensación de Ryan ha sido consistente con los resultados de la empresa en el último año.
CEO
Ryan Spencer (46 yo)
4.9yrs
Permanencia
US$5,810,736
Compensación
Mr. Ryan Spencer serves as Independent Director at Cidara Therapeutics, Inc. from April 24, 2024. He serves as the Chief Executive Officer and Director of Dynavax Technologies Corporation since December 16...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$5.81m | 0.17% $ 2.8m | |
| President & COO | 11.7yrs | US$2.99m | 0.024% $ 388.6k | |
| Senior VP & CFO | 3.7yrs | US$2.07m | 0.0059% $ 93.6k | |
| Chief Medical Officer and Senior VP of Clinical Development | 11.3yrs | US$1.88m | 0.049% $ 782.0k | |
| Chief Accounting Officer & Controller | 4.5yrs | sin datos | sin datos | |
| Senior VP & Chief Human Resources Officer | 5.8yrs | sin datos | sin datos | |
| VP of Investor Relations & Corporate Communications | 1.8yrs | sin datos | sin datos | |
| Senior VP & General Counsel | 3.4yrs | sin datos | sin datos | |
| Senior VP & Chief Commercial Officer | no data | sin datos | sin datos | |
| Senior Vice President of Vaccine Research | 3.8yrs | sin datos | sin datos | |
| VP, Site Head & MD for Dynavax GmbH | 3.8yrs | sin datos | sin datos | |
| Senior Vice President of Technical Operations | 3.8yrs | sin datos | sin datos |
3.8yrs
Permanencia media
59.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de DVAX se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4.9yrs | US$5.81m | 0.17% $ 2.8m | |
| Independent Director | 18.3yrs | US$298.73k | 0.021% $ 337.6k | |
| Independent Director | 14.3yrs | US$290.73k | 0.0011% $ 18.2k | |
| Independent Director | 15yrs | US$278.73k | 0.016% $ 253.6k | |
| Member of Scientific Advisory Board | 1.8yrs | US$1.83m | sin datos | |
| Member of Scientific Advisory Board | 6.4yrs | sin datos | sin datos | |
| Independent Director | 4.3yrs | US$293.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.4yrs | US$20.00k | sin datos | |
| Independent Chairman of the Board | 3.1yrs | US$323.73k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.4yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.4yrs | sin datos | sin datos |
6.4yrs
Permanencia media
73.5yo
Promedio de edad
Junta con experiencia: La junta directiva de DVAX se considera experimentada (6.4 años de antigüedad promedio).